See What HealthDay Can Do For You
Contact Us

Post-Prostatectomy Erectile Dysfunction Helped by Statin

Twice as many men on statins have sexual function six months after surgery as sildenafil-only patients

FRIDAY, Aug. 10 (HealthDay News) -- Men with prostate cancer who take statins are less likely to have erectile dysfunction after nerve-sparing surgery than those taking sildenafil alone, researchers report in the August issue of the Journal of Urology.

Sang Eun Lee, M.D., of Seoul National University Bundang Hospital in Seongnam, Korea, and colleagues randomized 50 prostate-cancer patients scheduled to have bilateral nerve sparing radical retropubic prostatectomy into two groups. One took 50 milligrams of sildenafil daily if needed; the second took 10 mg daily atorvastatin for three months plus sildenafil if needed. The patients did not have erectile dysfunction prior to surgery or hypercholesterolemia.

Six months after surgery, 26.1 percent of sildenafil-alone patients were potent, versus 55 percent of atorvastatin patients; 17.4 percent of sildenafil-alone patients reported having intercourse via vaginal penetration without using a phosphodiesterase-5 inhibitor, versus 40 percent of atorvastatin patients.

"Postoperative treatment with atorvastatin in men who report normal erectile function preoperatively may contribute to earlier recovery of erectile function after nerve sparing radical retropubic prostatectomy," the authors write.

The study was funded by the Seoul National University Bundang Hospital Research Fund.

Full Text (subscription or payment may be required)

Physician's Briefing